Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids.

ABSTRACT: Thyroid cancer is the most common endocrine malignancy and several genetic events have been described to promote the development of thyroid carcinogenesis. Besides the effects of specific mutations on thyroid cancer development, the molecular mechanisms controlling tumorigenesis, tumor behavior, and drug resistance are still largely unknown. Cancer organoids have been proposed as a powerful tool to study aspects related to tumor development and progression and appear promising to test individual responses to therapies. Here, using mESC-derived thyroid organoids, we developed a Braf^V637E-inducible model able to recapitulate the features of papillary thyroid cancer in vitro. Overexpression of the murine Braf^V637E mutation, equivalent to Braf^V600E in humans, r

SUBMITTER: Lasolle H 

PROVIDER: S-EPMC10786723 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature